click below
click below
Normal Size Small Size show me how
TRU Pharm 2020
Term | Definition |
---|---|
Tensilon | (Edrophonium) Mode of action: Indirect acting cholinergic A primary use: Diagnosing neuromuscular weakness due to Myasthenia Gravis Timings: Very quick half life (10 min); very rapid onset |
Methacholine | Mode of action: Direct acting cholinergic (same structure of acetylcholine) A Primary use: Used diagnostically in Pulmonary Function to rule out Asthma |
Cocaine | Mode of action: Indirect acting adrenergic A primary use: Local vasoconstrictor and local anesthetic; rarely used for this purpose |
Ventolin | (Salbutamol) Mode of action: Direct acting B2 agonist A primary use: A rescue Bronchodilator Dosages: MDI = 100ug, Nebulue = 2.5-5.0mg Timings: Onest = 5-15 min, Peak effect = 30-60 min, Duration 4-6 hours |
Bricanyl | (Terbutaline) Mode of action: Direct acting B2 agonist A primuary use: Bronchodilator (not used that much) Only comes in a dry powdered form (e.g. not able to give through a ventilator circuit) |
Serevent | (Salmeterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy for Asthma and COPD Timings: Lasts 12 hours; slower onset (15-20 mins) |
Oxeze | (Formoterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy for COPD and Asthma. Possible reliever of acute symptoms as well due to is fast onset. Timings: Quick onset (5 mins); 12 hour duration |
Onbrez | (Indacaterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy in COPD and Asthma Timings: 24 hr duration |
Atrovent | (Ipratropium Bromide) Mode of action: Direct acting Muscarinic Antagonist (E.g. Anti-cholinergic or Anti-muscainic) A primary effect: Act as a short acting bronchodilator (reliever) Timings: Onset 15-20 min; Peak effect 1-2 hours; Duration 4-6 hours |
Combivent | Mode of action: SABA and SAMA A combination of Ventolin and Atrovent A primary use: Reliever for acute bronchoconstriction |
Spiriva | (Tiotropium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (maintenance) Timings: Long acting agent (24 hours); once daily dosing |
Seebri | (Glycopyrronium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent (24 hours); once daily dosing |
Tudorza | (Aclidinium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent with high enough dosing (12-24 hours); once or twice daily dosing |
Incruse | (Umeclidinium): Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent (24 hours); once daily dosing |
Anoro | Combination LAMA + LABA Vilanterol + Umeclidinium |
Ultibro | Combination LAMA + LABA Indacaterol + Glycopyrronium |
Inspiolto | Combination LAMA + LABA Olodaterol + Tiotropium |
Duaklir | Combination LAMA + LABA Formoterol + Aclidinium |
Caffeine | Mode of action: Methylxanthine; increases central chemoreceptor sensitivity to CO2 A primary use: Treating apnea of prematurity |
Theophylline | Mode of action: Methylxanthine; can inhibit Phospho-diesterase-enzyme and adenosine which increases cAMP A primary use: Bronchodilation Side effects: Low therapeutic index |
Aminophylline | Mode of action: Methylxanthine; can inhibit Phospho-diesterase-enzyme and adenosine which increases cAMP A primary use: Bronchodilation Side effects: Easier to titrate dose compared to Theophylline as less potent |
Cortef | (Hydrocortisone) Mode of action: Acts on intracellular corticosteroid receptors. A primary use: Systemic steroid. Used as a replacement in those with decreased normal production as it is similar to cortisol, |
Prednisone | Mode of action: Acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Used in acute respiratory (asthma) exacerbations and to suppress auto-immune diseases. Very common. |
Decadron | (Dexamethasone) Mode of action: Acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Potent systemic steroid. Reserved for cases where quicker effects are needed. |
Flovent | (Fluticasone Propionate) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Very common; used for maintenance of Asthma symptoms |
Pulmicort | (Budesonide) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Maintenance of Asthma symptoms; can be nebilized. |
Arnuity | (Fluticasone Furoate) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Maintenance of Asthma symptoms. Once daily dosing. |
Alvesco | (Ciclesonide) Mode of action: Inhaled agent. Is a Prodrug and is inactive until comes in contact with respiratory epithelium. Once in contact, is converted to effective corticosteroid A primary use: Maintenance of Asthma symptoms. |
Accolate | (Zafirlukast) Mode of action: Leukotriene receptor antagonists; competitive antagonist A primary use: And add-on therapy to reducing inflammation in Asthma |
Singulair | (Montelukast) Mode of action: Leukotriene receptor antagonists; competitive antagonist A primary use: And add-on therapy to reducing inflammation in Asthma |
Xolair | (Omalizumab) Mode of action: Anti-IgE; binds to free circulating IgE which prevents it binding to mast cells A primary use: Add on therapy to reduce inflammation in Asthma |
Nucala | (Mepolizumab) Mode of action: Anti-interleukin 5; binds to free circulating IL-5 which prevent its binding to receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
Cinqair | (Reslizumab) Mode of action: Anti-interleukin 5; binds to free circulating IL-5 which prevent its binding to receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
Fasenra | (Benralizumab) Mode of action: Anti-interleukin 5; competitively binds to IL-5 receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
Daxas | (Roflumilast) Mode of action: Phosphodiesterase 4 inhibitor; blocks action of phosphodiesterase 4 which increases cAMP in some inflammatory cells A primary use: Add-on therapy in reducing symptoms in those with severe COPD |
Advair | Serevent & Fluticason Combination LABA+ICS |
Symbicort | Formoterol & Budesonide Combination LABA+ICS |
Zenhale | Fomoterol & Mometasone Combination LABA+ICS |
Breo | Vilanterol & Fluticasone Furoate Combination LABA+ICS |
Trelegy | Breo + Umeclidinium Combination of 3 agents: LABA + ICS + LAMA |
Mucomyst | (N-Acetylcysteine) Mode of action: Breaks up di-sulphide bonds that link mucus together A primary use: As a mucolytic. Is used for other things as well (tylenol overdose treatment) Other: Often causes bronchoconstriction and irritation; bad odor |
Pulmozyme | (Dornase-Alfa): Mode of action: Breaks up DNA present in mucus A primary use: A mucolytic for those suffering from cystic fibrosis |
Hypertonic Saline: | Mode of action: Draws in surrounding fluid due to its hypertonic nature A primary use: As an expectorant (drawing more fluid means increasing amount of mucus) |
Dextromethorphan: | Mode of action: Suppresses medulla cough center A primary use: Commonly found compound in anti-cough/cold medications |
Codeine: | Mode of action: Suppresses medulla cough center A primary use: Commonly found compound in anti-cough/cold medications |
Robinul | (Glycopyrrolate): Mode of action: Anti-Muscarinic A primary use: Used to dry out secretions due to its anti-muscarinic effects |
Scopolamine: | Mode of action: Anti-Muscarinic A primary use: Used to dry out secretions due to its anti-muscarinic effects |
Esbriets | (Pirfenidone): Mode of action: Slows down fibroblast growth A primary use: Used in idiopathic pulmonary fibrosis to slow progression of fibrosis |
OFEV | (Nintedanib): Mode of action: Slows down fibroblast growth A primary use: Used in idiopathic pulmonary fibrosis to slow progression of fibrosi |